Lectin Affinity Plasmapheresis for Middle East Respiratory Syndrome-Coronavirus and Marburg Virus Glycoprotein Elimination | Zendy

Benjamin Koch | Zendy; Patricia Schult-Dietrich | Zendy; Stefan Büttner | Zendy; Bijan Dilmaghani | Zendy; Dario Lohmann | Zendy; Patrick C. Baer | Zendy; Ursula Dietrich | Zendy; Helmut Geiger | Zendy

Open Access

Lectin Affinity Plasmapheresis for Middle East Respiratory Syndrome-Coronavirus and Marburg Virus Glycoprotein Elimination

Author(s) -

Benjamin Koch,

Patricia Schult-Dietrich,

Stefan Büttner,

Bijan Dilmaghani,

Dario Lohmann,

Patrick C. Baer,

Ursula Dietrich,

Helmut Geiger

Publication year - 2018

Publication title -

blood purification

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.686

H-Index - 57

eISSN - 1421-9735

pISSN - 0253-5068

DOI - 10.1159/000487224

Subject(s) - marburg virus , glycoprotein , plasmapheresis , virology , middle east respiratory syndrome coronavirus , infectivity , virus , medicine , immunology , biology , covid-19 , antibody , microbiology and biotechnology , ebola virus , disease , infectious disease (medical specialty)

Middle East respiratory syndrome coronavirus (MERS-CoV) and Marburg virus (MARV) are among the World Health Organization's top 8 emerging pathogens. Both zoonoses share nonspecific early symptoms, a high lethality rate, and a reduced number of specific treatment options. Therefore, we evaluated extracorporeal virus and glycoprotein (GP) elimination by lectin affinity plasmapheresis (LAP).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research